---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-255110"
form_type: "8-K"
ticker: "STIM"
cik: "0001227636"
company_name: "Neuronetics, Inc."
filed_at: "2024-11-12T23:59:59+00:00"
generated_at: "2026-05-30T01:35:21.983849+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Neuronetics Q3 revenue up 4% to $18.5M; net loss widens to $13.3M; stockholders approve Greenbrook deal

## Summary
- Revenue $18.5M (+4% YoY); U.S. system revenue $4.1M (+14%) on 48 units; treatment session revenue $13.3M (+2%)
- Gross margin improved to 75.6% from 65.8% due to product mix and absence of prior-year manufacturing costs
- Net loss widened to $13.3M ($0.44/sh) from $9.4M ($0.33/sh) in Q3 2023; EBITDA -$11.6M vs -$7.7M; cash $20.9M
- Stockholders approved Greenbrook acquisition Nov 8; court hearing Nov 15; expect cash flow breakeven by Q2 2025
- Full-year 2024 revenue guidance narrowed to $71-72M; Q4 2024 revenue guidance $19-20M

## SEC filing metadata
- accession: 0001193125-24-255110
- form_type: 8-K
- ticker: STIM
- cik: 0001227636
- company_name: Neuronetics, Inc.
- filed_at: 2024-11-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1227636/000119312524255110/0001193125-24-255110-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1227636/000119312524255110/d910083d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-255110
- JSON: https://secwatch.observer/filing/0001193125-24-255110.json
- Plain text: https://secwatch.observer/filing/0001193125-24-255110.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.